ICYMI, some of this week’s featured content includes late breaking research results coming out of AAD VMX 2021. Plus, stories on sun protection to prevent skin cancer, microneedling strategies, and more.
This week’s edition of The Mainstream Patient features stories on cryptocurrency for cosmetic procedures, tattoo removal, full-size sunscreen in carry-on bags, using ice on the face, plus more.
Catch up on all of the latest news coming out of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021).
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.
A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.
In recent phase 3 trials, deucravacitinib demonstrated progress toward becoming a potential new treatment in moderate to severe plaque psoriasis.
Revance presents 4 AAD VMX ePoster abstracts examining phase 3 study data for DAXI, and the impact of HA filler manufacturing technologies on HA chain degradation.
More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.
In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.
Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
A survey found a large proportion of dermatologists surveyed said their patients referenced video conferencing as the reason for seeking cosmetic consultation since the start of the pandemic.
In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.
Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.
Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.
Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
The American Academy of Dermatology Announced the results from its annual election, with 2 officers and 4 board members assuming their new positions in March 2022.
In a presentation at the American Academy of Dermatology Virtual Meeting, Marcia S. Driscoll, MD, PharmD, gave guidelines for diagnosing and treating four dermatoses of pregnancy.
Thanks to new drug approvals, medical management is replacing surgery as the first-line treatment for inflammation caused by hidradenitis suppurativa. However, surgery is often necessary to relieve pain related to tunnels.
Patients of color make up a growing market for aesthetic dermatology. Physicians must learn how to tailor treatments and assess skin of color risk to best serve this emerging patient population. Doing so will deliver positive outcomes and drive patient satisfaction.
Telemedicine flourished among dermatology practices in the wake of COVID-19. But as the world tentatively reopens, questions about connectivity, regulations, and payment will have to be addressed before physicians decide what role virtual visits will play in their practices.
Futuristic tools including robotics and new types of lasers are just some of the therapeutic innovations aimed at slowing hair loss and increasing hair growth.
New data on the safety and efficacy of roflumilast foam (ARQ-154, Arcutis Biotherapeutics) for scalp and body psoriasis was presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.
According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.